BioCardia has completed enrollment and dosing of the low-dose cohort in its CardiALLO Phase I/II trial, targeting ischemic heart failure patients with elevated markers of heart stress and inflammation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.